ACLX-001 is under clinical development by Arcellx and currently in Phase I for Refractory Multiple Myeloma. According to GlobalData, Phase I drugs for Refractory Multiple Myeloma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ACLX-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ACLX-001 overview

ACLX-001 is under development for the treatment of multiple myeloma, relapsed multiple myeloma and refractory multiple myeloma. The drug candidate is administered through the parenteral route. The drug candidate comprises autologous antigen receptor complex (ARC) T cells and a bivalent SparX (soluble protein antigen-receptor X-linker) protein targeting BCMA. The drug candidate acts by targeting cells expressing BCMA. The drug candidate is being developed based on ARC-SparX platform.

It was under development for treatment of autoimmune disease

Arcellx overview

Arcellx is a biopharmaceutical company which develops, manufactures and markets novel and adaptive cell therapies for the treatment of cancer, acute myeloid leukemia, solid tumors and autoimmune diseases. Arcellx is headquartered in Gaithersburg, Maryland, the US.

For a complete picture of ACLX-001’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.